A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin

Journal of Human Genetics

Volumn 49, Issue 10, 2004, Pages 582-585

  Ishikawa, Chikako ^a   Ozaki, Hiroshi ^b   Nakajima, Toshiaki ^c   Ishii, Toshihiro ^b   Kanai, Saburo ^b   Anjo, Saeko ^a   Shirai, Kohji ^b   Inoue, Ituro ^c  

^a TOHO UNIVERSITY   (Japan)

^b TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; NUCLEOTIDE;

ARTICLE; DNA SEQUENCE; ENZYME ACTIVITY; EXON; FRAMESHIFT MUTATION; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; METABOLISM; RHABDOMYOLYSIS;

AGED; ARYL HYDROCARBON HYDROXYLASES; EXONS; FEMALE; FRAMESHIFT MUTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRIDINES; RHABDOMYOLYSIS;

EID: 8644235696     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-004-0188-6     Document Type: Article

References (12)

1. Farmer JA (2001) Learning from the cerivastatin experience. Lancet 358:1383-1385
2. Lamba J, Lin Y, Thummel K, Daly A, Watkins P, Strom S, Zhang J, Schuetz E (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121-132
3. Matushima S, Maeda K, Shitara Y, Sasaki M, Suzuki H, Sugiyama Y (2002) Estimation of a double-transfectanted MDCK II monolayer co-expressing human OATP2 and MRP2. Jpn Pharmacol Ther 30:8441-8444
4. Mück W (2000) Clinical phaimacokinetics of cerivastatin. Clin Pharmacokinet 39:99-116
5. Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S, Inoue M, Kuroiwa Y, Yokoi T (2003) Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos 31:687-690
6. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T (2000) Inhibitory effect of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Clin Pharmacol 49:244-253
7. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW (1994) Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546
8. Rossenson R (2004) Current overview of statin-induced myopathy. Am J Med 116:408-416
9. Staffa J, Chang J, Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539-540
10. Stein E (1998) Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am J Cardiol 82:40J-46J
11. Wang J-S, Neuvonen M, Wen Z, Backman JT, Neuvonen PJ (2002) Gemfibrozil inhibits CYC2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30:1352-1356
12. Yamazaki H, Suzuki M, Shimada N, Nakajima M, Yokoi T (2000) In vitro effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica 30:61-70